超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國BG Medicine, Inc.
BG Medicine是一家致力于發現、開發和商品化以生物標志物為基礎的新型分子診斷技術，并借此來改善患者治療結果和控制醫療費用的生命科學公司。該公司宣布，在D輪融資中獲得總額為4000萬美元的資金。此輪融資包括新投資者Legg Mason Capital Management、GE Asset Management、SMALLCAP World Fund和現有投資者Flagship Ventures、Gilde Healthcare Partners、Humana、Stelios Papadopoulos。該筆資金將用于推動公司現有的兩個診斷產品的研發和商業化，并將支持公司繼續進行其他產品的研發。




BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. Our technology platform uniquely positions us to rapidly and cost-effectively discover new high-value biomarkers over a broad range of therapeutic categories that promise to be highly correlated to clinical outcomes. We have built a broad product pipeline that focuses on cardiovascular disease, cancer and CNS disorders through academic collaborations and initiatives with major pharmaceutical companies, the U.S Food and Drug Administration, or FDA and other healthcare organizations.

We discover biomarkers employing our proprietary, versatile, scalable technology platform that enables us to identify new biomarkers by integrating, and automating measurement, analysis, characterizations and interpretations of proteins and small non-protein biological molecules, or metabolites, collected from bodily fluids.

Through our biomarker discovery and product development programs we develop molecular diagnostic tests that are intended to provide information to physicians that will greatly improve patient treatment decisions. Our tests are designed to predict a patient’s response to drug therapy, determine the potential toxicity of therapeutic agents to patients, identify patients who have or are likely to develop a specific disease, predict a patient’s prognosis once a disease has been diagnosed and monitor a patient’s disease progression or drug response.